Zuppone Stefania, Fabbrini Maria Serena, Vago Riccardo
Urological Research Institute, Division of Experimental Oncology, IRCCS San Raffaele Hospital, 20132 Milan, Italy.
MIUR, Italian Ministry of Instruction, University and Research, 20090 Monza, Italy.
Biomedicines. 2019 May 17;7(2):38. doi: 10.3390/biomedicines7020038.
For the recombinant expression of toxin-based drugs, a crucial step lies not only in the choice of the production host(s) but also in the accurate design of the protein chimera. These issues are particularly important since such products may be toxic to the expressing host itself. To avoid or limit the toxicity to productive cells while obtaining a consistent yield in chimeric protein, several systems from bacterial to mammalian host cells have been employed. In this review, we will discuss the development of immunotoxin (IT) expression, placing special emphasis on advantages and on potential drawbacks, as one single perfect host for every chimeric protein toxin or ligand does not exist.
对于基于毒素的药物的重组表达,关键步骤不仅在于生产宿主的选择,还在于蛋白质嵌合体的精确设计。这些问题尤为重要,因为此类产品可能对表达宿主本身有毒性。为了在获得嵌合蛋白一致产量的同时避免或限制对生产细胞的毒性,已经采用了从细菌到哺乳动物宿主细胞的多种系统。在本综述中,我们将讨论免疫毒素(IT)表达的发展,特别强调其优点和潜在缺点,因为不存在适用于每种嵌合蛋白毒素或配体的单一完美宿主。